Fidaxomicin Prophylaxis Against Clostridium difficile in Stem-Cell Transplant Recipients

Is fidaxomicin prophylaxis justified in hematopoietic stem-cell recipients?

In patients receiving hematopoietic stem-cell transplant therapy (HSCT), Clostridium difficile infection (CDI) is common and may result in additional complications including increased risk for graft-versus-host disease (GVHD). Thus, strategies to prevent CDI in HSCT recipients are needed. In this multicenter study, 600 autologous or allogeneic HSCT recipients receiving fluoroquinolone prophylaxis were randomized to fidaxomicin 200 mg daily or placebo until 7 days after engraftment or completion of antibiotics (given for prophylaxis or treatment). Study drug could not continue past posttransplant day 40 (mean treatment duration, 22–23 days). The primary composite endpoint included confirmed CDI, missing CDI assessment, or receipt of treatmen…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Fidaxomicin Prophylaxis Against Clostridium difficile in Stem-Cell Transplant Recipients

Topics

Reviewing Author